desipramine has been researched along with Mood Disorders in 11 studies
Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.
desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.
Mood Disorders: Those disorders that have a disturbance in mood as their predominant feature.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with neuropathic pain often experience depression and anxiety both of which are known to be temporally correlated with noradrenergic dysfunction in the locus coeruleus (LC) as pain becomes chronic." | 1.48 | The onset of treatment with the antidepressant desipramine is critical for the emotional consequences of neuropathic pain. ( Alba-Delgado, C; Berrocoso, E; Llorca-Torralba, M; Mico, JA, 2018) |
| "Tranylcypromine was effective in the treatment of 14 patients meeting both the National Institute of Mental Health and DSM-III-R criteria for winter depression." | 1.28 | Pharmacological responsiveness of winter depression. ( Del Medico, VJ; Dilsaver, SC; Jaeckle, S; Quadri, A, 1990) |
| "Treatment with desipramine in vivo (10 mg/kg body weight/day) caused a down-regulation of 3H-enkephalinamide binding in the basal ganglia and the hippocampus, while no effects could be observed in the cerebral cortex and the rest of the forebrain." | 1.27 | Opioid peptides and receptors in relation to affective illness. Effects of desipramine and lithium on opioid receptors in rat brain. ( Schou, M; Stengaard-Pedersen, K, 1985) |
| "Symptomatic orthostatic hypotension, the most common side effect encountered, occurred early in treatment at low desipramine plasma concentrations." | 1.26 | Major adverse reactions during desipramine treatment: relationship to plasma drug concentrations, concomitant antipsychotic treatment, and patient characteristics. ( Bock, J; Bowers, MB; Jatlow, PI; Nelson, JC; Quinlan, DM, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (54.55) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alba-Delgado, C | 1 |
| Llorca-Torralba, M | 1 |
| Mico, JA | 1 |
| Berrocoso, E | 1 |
| Stratinaki, M | 1 |
| Varidaki, A | 1 |
| Mitsi, V | 1 |
| Ghose, S | 1 |
| Magida, J | 1 |
| Dias, C | 1 |
| Russo, SJ | 1 |
| Vialou, V | 1 |
| Caldarone, BJ | 1 |
| Tamminga, CA | 1 |
| Nestler, EJ | 1 |
| Zachariou, V | 1 |
| Campeau, S | 1 |
| Liberzon, I | 1 |
| Morilak, D | 1 |
| Ressler, K | 1 |
| Nelson, JC | 1 |
| Jatlow, PI | 1 |
| Bock, J | 1 |
| Quinlan, DM | 1 |
| Bowers, MB | 1 |
| Prakash, R | 1 |
| Brambilla, F | 1 |
| Smeraldi, E | 1 |
| Sacchetti, E | 1 |
| Bellodi, L | 1 |
| Genazzani, AR | 1 |
| Facchinetti, F | 1 |
| Müller, EE | 1 |
| Amsterdam, JD | 1 |
| Winokur, A | 1 |
| Caroff, S | 1 |
| Levin, RM | 1 |
| Treisman, GJ | 1 |
| Angelino, AF | 1 |
| Hutton, HE | 1 |
| Dilsaver, SC | 2 |
| Del Medico, VJ | 1 |
| Quadri, A | 1 |
| Jaeckle, S | 1 |
| Stengaard-Pedersen, K | 1 |
| Schou, M | 1 |
2 reviews available for desipramine and Mood Disorders
| Article | Year |
|---|---|
Stress modulation of cognitive and affective processes.
Topics: Acoustic Stimulation; Affect; Animals; Attention; Cognition; Decision Making; Desipramine; Extinctio | 2011 |
Pharmacologic induction of cholinergic system up-regulation and supersensitivity in affective disorders research.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Bipolar Disorder; Brain; Depressio | 1986 |
1 trial available for desipramine and Mood Disorders
| Article | Year |
|---|---|
Evaluation of role of the biogenic amines in affective illness: a clinical strategy.
Topics: Antidepressive Agents; Biogenic Amines; Brompheniramine; Clinical Trials as Topic; Desipramine; Huma | 1982 |
8 other studies available for desipramine and Mood Disorders
| Article | Year |
|---|---|
The onset of treatment with the antidepressant desipramine is critical for the emotional consequences of neuropathic pain.
Topics: Action Potentials; Analysis of Variance; Animals; Antidepressive Agents, Tricyclic; CREB-Binding Pro | 2018 |
Regulator of G protein signaling 4 [corrected] is a crucial modulator of antidepressant drug action in depression and neuropathic pain models.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antidepressive Agents; Behavior, Animal; Brain; | 2013 |
Major adverse reactions during desipramine treatment: relationship to plasma drug concentrations, concomitant antipsychotic treatment, and patient characteristics.
Topics: Adult; Age Factors; Aged; Antipsychotic Agents; Constipation; Delirium; Depressive Disorder; Desipra | 1982 |
Neuroendocrine abnormalities in depressive illness.
Topics: Adrenocorticotropic Hormone; Adult; Aged; beta-Endorphin; beta-Lipotropin; Depressive Disorder; Desi | 1982 |
The effects of desmethylimipramine and lithium on human sperm function.
Topics: Adult; Desipramine; Humans; Lithium; Male; Middle Aged; Mood Disorders; Sperm Count; Sperm Motility; | 1981 |
Psychiatric issues in the management of patients with HIV infection.
Topics: Adult; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Depressive Disorder, Ma | 2001 |
Pharmacological responsiveness of winter depression.
Topics: Adult; Antidepressive Agents; Bupropion; Depressive Disorder; Desipramine; Disorders of Excessive So | 1990 |
Opioid peptides and receptors in relation to affective illness. Effects of desipramine and lithium on opioid receptors in rat brain.
Topics: Animals; Brain; Brain Chemistry; Desipramine; Electroshock; Endorphins; Humans; In Vitro Techniques; | 1985 |